Biofrontera inc.BFRIW.US Overview
US StockHealthcare
(No presentation for BFRIW)
BFRIW Overall Performance
BFRIW AI Analysis & Strategy
BFRIW Recent Performance
-
Biofrontera inc.
0.81%
Avg of Sector
-1.14%
S&P500
BFRIW PowerScanner
BFRIW Key Information
BFRIW Valuation Metrics
BFRIW Earnings Table
BFRIW Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.